A Summer Project Report On

Prelaunch Survey of Ramipril And Ramipril Hydrochlorothiazide Combination

Submitted in partial fulfillment of the requirement for Master of Business Administration (MBA Pharmaceuticals) Submitted to

Kadi Sarva Vishwavidyalaya Sector-15 Gandhinagar-382015 May-June-2010

Submitted By Project Guide

Hardik V. Patel
MBA (PHARMA)

CERTIFICATE FROM THE INSTITUTE

This is to certify that the contents of this report entitled Prelaunch Survey of Ramipril and Ramipril Hydrochlorothiazide Combination by Hardik V Patel, Roll No. 52, MBA (Pharma) submitted to Kadi Sarva Vishwavidyalaya, Gandhinagar, for the partial fulfillment of award of Master of Business Administration is original research work carried out by him. This report, to the best of my knowledge, has not been submitted either partly or fully to any other University or Institute for award of any degree or diploma.

Date: 15/07/2010 Place: Gandhinagar

Dr. G.B.Shah Principal, KBIPER

MY ENTIRE WORK OF PROJECT HAS BEEN DEDICATED TO GOD, MY LOVING PARENTS, & WHO MY MY ELDER FRIENDS BROTHER

ALWAYS

SUPPORTED ME.

DECLARATION
I, Mr. Hardik V. Patel, student of the MBA (Pharma) affiliated to Kadi Sarva Vishwavidyalaya, Gandhinagar hereby declare that this project is a result of culmination of my sincere efforts.

I declare that this submitted work is done solely by me and to the best of my knowledge. I have tried at my level best to collect precise detail to provide useful information to the company.

I also declare that all the information collected from various sources has been duly acknowledged in this project report.

Hardik V. Patel MBA (Pharma) Kadi Sarva Vishwavidyalaya

ACKNOWLEDGEMENT
Here, I take this opportunity to humbly express my gratitude to all those concerned with my project entitled Prelaunch survey of Ramipril and Ramipril Hydrochlorothiazide Combination. I would like to share the success of my project amongst the person who has directly and indirectly helped me to complete this project. In providing concrete shape of my project, there are numerous people who have taken part. I take this opportunity to express my deep sense of gratitude and hearty thanks to my Professor Mrs. Mallika Babu for her efforts to get training in the company. I am hearty thankful to her for providing me her valuable suggestions and remarks to complete this project. Her extensive knowledge of subject and the way, she imparted the same to me has enabled me to develop the project cohesive manner. We are highly obliged to Mr. Maulesh Shah . For allocating such an interesting project. In spite of being very busy, they were ready to help me whenever required. The whole staff of Kamron Laboratories Ltd. was co-operative and I am thankful for all the support they extended to me. A special thanks to my friends Mr. Sumit Tiwari and Mr. Yashrajsinh Rathod for his continuous support and guidance made my work very easy. I would like to express my heartiest thanks to my family, parents and brother to extend their help as and when required. I would like to thank my friends- Arshad, Gunjan and Ronak. Without their support this would not be possible. My guide at the institute shared his expertise knowledge, so I sincerely thank to Principal Dr. G.B.Shah and Dr. Srikalp Deshpande.

Hardik V. Patel

PREFACE
Summer training is an essential part of curriculum of MBA, affiliated to Kadi Sarva Vishwavidyalaya, and it is compulsory for every student. Management colleges provide their students theoretical knowledge but it remains incomplete without practical knowledge. Moreover students of MBA are required to gather maximum practical exposure towards corporate world. This experience provides the best of knowledge for any MBA students which cant be attained in class-room teaching. Through this project report work I can better understand the different aspects like research design, measurement and scaling techniques, questionnaire and its design, data collection, analysis and interpretation. Through this report I can understand business research methodology in practical term. The major emphasize of my work was to analyze the current market scenario of Ramipril and Ramipril hydrochlorothiazide. The working experience with Kamrom laboratories ltd., Kalol, Gandhinagar, was very exciting and it has created a long lasting impression in my mind. This project gave me immense opportunities to upgrade my knowledge related to marketing field and also gave me a chance to learn and understand the strategies to be kept in mind while launching a new product.

EXECUTIVE SUMMERY
Kamron Laboratories Ltd., has been set up in 1990 for manufacture of pharmaceutical formulations in dosage forms like Tablets, Capsules, Liquid Orals, Dry Syrups, Eye Drops and Injections. They have divided their products in three different groups as follows.1) Panchratna Brands 2) Platinum Blue Group: Platinum Green 3) Titanium Brands. I had done my summer project under titanium brands. The objective of my project was to do a survey of molecules Ramipril and Ramipril Hydrochlorothiazide combination in various areas of Ahmedabad to find out the market potential of given molecules. In first section of my report I had given brief information about pharmaceutical industry and in second section I had given brief information of Kamron laboratories ltd. In the main part of my project, I analyzed various parameters based on the survey conducted of 150 chemists of mentioned areas. The main potential seller of Ramipril and Ramipril Hydrochlorothiazide are Sanofi Aventis (Cardace), Micro Cardicare (Hopace), Alkem (Race), Cipla (Ramipres), Lupin (Ramistar), Macleods (Macpril) etc. At the end of the project, I had given my own findings and few of suggestions to guide the launch of these two molecules.

TABLE OF CONTENT
Sr no.
1

Content
Introduction of Indian pharmaceutical industry Advantage India The growth scenario Cardiovascular drug market Major players in Indian market

Page no

Company profile About Kamron Core values of Kamron laboratories ltd Vision statement of Kamron Mission statement Kamron Facilities Research & development Quality assurance International certifications Brand management team Product list

Data analysis Objectives Research methodology: Working area: Research design: Plan of work: About the molecules Data interpretation Findings Suggestions Limitation of survey References Appendix

LIST OF GRAPH
Sr no.
1
2 3

Graph Content
Sale of number of strips per week of different companies Percentage of total sale Sale Of Strip Of Ramipril And Ramipril Hydrochlorothiazide (Strength wise)

Page no

Sale Of Strip Of Ramipril And Ramipril Hydrochlorothiazide (Dosage form wise)

5 6

Unit percentage value Total sale(Regular Vs New Prescription)

LIST OF TABLE
Sr no.
1 2 3 4 5 6

Table Content
Indias domestic pharmaceutical market Brand classification of Kamron Available brands in the market Sale of number of strips per week of different companies Percentage of total sale Sale of strip of Ramipril and Ramipril hydrochlorothiazide(strength wise)

Page no

Sale of strip of Ramipril and Ramipril hydrochlorothiazide (dosage form wise)

8 9

Unit percentage value Analysis of regular sale and new prescription.

PROJECT REPORT

Introduction of Indian Pharmaceutical industry

The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs at affordable prices are available to the vast population of this sub-continent.

-Richard Gerster
The future depends on what we do in the present India is the worlds fourth largest producer of pharmaceuticals by volume, accounting for around 8% of global production. In value terms, production accounts for around 1.5% of the world total. The Indian pharmaceutical industry directly employs around 500,000 people and is highly fragmented having more then 20000 companies. While there are around 270 large R&D based pharmaceutical companies in India, including multinationals, government-owned and private companies, there are also around 5,600 smaller licensed generics manufacturers. The Indian Pharmaceutical industry currently tops the chart amongst India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high amongst all the third world countries, in terms of technology, quality and the vast range of medicines that are manufactured. Indian Pharmaceutical Industry ranks fourth in the world, pertaining to the volume of sales. The estimated worth of the Indian Pharmaceutical Industry is Rs.55,454 Crores. The growth rate of the industry is about 13% per year. Almost most 70% of the domestic demand for bulk drugs is catered by the Indian Pharma Industry. The Pharma Industry in India produces around 20% to 24% of the global Generic drugs. The Indian Pharmaceutical Industry is one of the biggest producers of the Active Pharmaceutical Ingredients (API) in the international arena. The Indian Pharma sector leads the science-based industries in the country. Around 40% of the

total pharmaceutical produce is exported. 55% of the total exports constitute of formulations and the other 45%comprises of bulk drugs. The Indian Pharma Industry includes small scaled, medium scaled, large scaled players, which totals nearly 300 different companies. As per the present growth rate, the Indian Pharma Industry is expected to be a US$ 20 billion industry by the year 2015. The Indian Pharmaceutical sector is also expected to be among the Top Ten Pharma based markets in the world in the next ten years. The sales of the Indian Pharma Industry would worth US$ 43 billion within the next decade. The multinational companies, investing in research and development in India may save up to 30% to 50% of the expenses incurred. The top revenue-generating therapeutic groups in the Rs 55,454 crore domestic markets are Anti-infective, Gaestro, Cardiac, Respiratory, Pain management and Vitamins. Incidentally, the vitamins, minerals and nutrients segment is the only area (among the ones tracked by ORG-IMS) where five of the top 10 players are foreign multinational firms.While the market leader is the Indian subsidiary of Germanys Merck Ltd, the other foreign MNCs among the top 10 are GlaxoSmithKline (GSK), Pfizer, Novartis and Abbott. Indian companies among the top 10 are Cipla, Ranbaxy, Wockhardt, Piramal Healthcare and Zydus Cadila.

Bussiness Standard
The domestic market of Indian pharmaceutical industry is likely to register 12%-13% growth in 2009, only marginally lower than the earlier projections of 15% as an impact of macroeconomic conditions, according to ORG IMS Research. The impact of macroeconomic factors is much less on the Indian companies compared to the global peers. In the next 4-5 years, this industry is expected to continue to grow at more than 10% to touch the $30 billion mark by 2020. In the long term, the domestic consumption is expected to keep growing at a healthy pace, because currently Indias healthcare spending is only 5.6% of the countrys gross domestic product (GDP), which is among the lowest globally.

Highly Fragmented Pharmaceutical Industry

The domestic pharmaceutical market is quite fragmented with the top five companies commanding only 22% market share. Cipla Ltd has become the largest and the fastest growing company among the top five companies, outclassing Ranbaxy Laboratories Ltd. Even the top 20 companies have a total market share of about 57% only in contrast to the global drug market dominated by the 10 largest companies that account for about 40% of global sales. The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India. These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations Indias Domestic Pharmaceutical Market Company Total Pharma Market Cipla Ranbaxy Glaxo Smithkline Piramal Healthcare Zydus Cadila Total of Top 5 Size ($ Billion) 6.9 0.36 0.34 0.29 0.27 0.24 1.53 Market Share (%) 100.0 5.3 5.0 4.3 3.9 3.6 22.1 Growth Rate (%) 9.9 13.4 11.5 -1.2 11.7 6.8

SOURCE : ORG MIS

[Table no-1]

ADVANTAGE INDIA
Competent workforce: India has a pool of personnel with high managerial and technical competence as also skilled workforce. It has an educated work force and English is commonly used. Professional services are easily available.

Cost-effective chemical synthesis: its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide variety of bulk drugs and exports sophisticated bulk drugs. Legal & Financial Framework: India has a 60 year old democracy and hence has a solid legal framework and strong financial markets. There is already an established international industry and business community. Globalization: The country is committed to a free market economy and globalization. Above all, it has a 70 million middle class market, which is continuously growing.

Consolidation: For the first time in many years, the international pharmaceutical industry is finding great opportunities in India. The process of consolidation, which has become a generalized phenomenon in the world pharmaceutical industry, has started taking place in India. THE GROWTH SCENARIO Indian contract research industry growing at 40-50 per cent The Indian contract research Industry has grown tremendously over the past few years. It has witnessed the emergence of several CROs in the area of drug discovery & development over the last decade. India to capture US$ 250-300 million or 10 per cent of global clinical trials by 2010. India is emerging as a favored global destination for global drug development companies. Recent changes in Indias healthcare policies and a maturing regulatory

environment have significantly brought down the risk of shifting more clinical research from the developed countries to India. The clinical research industry in India is presently estimated at over US$ 100 million. New product launches underlie market growth The market has been growing between 6-8 per cent over the last two years, primarily driven by new launches and to some extent by volumes. In the last two years, more than 3,900 new products (largely branded generics) have been launched in India, contributing about US$ 355.6 million (million) worth of market value. While the Indian pharma majors launched more than ten products per year, global MNCs averaged one or two annually.

Cardiovascular Drug Market [1]

Cardiovascular Drug Recent reports on cardiovascular drugs industry reveals that by the end of year 2010, the market for heart patients in America will rise to 251 million with the greatest rate of growth. The total market size of this industry is also expected to cross US $ 116.3 billion by the end of 2010. Of the whole cardiovascular drugs market, the anti hypertensive drugs sector is a leading segment with a total market share of around 50%. Sanofi-Aventis, Glaxo Smithkline, Novartis and Boehringer, Cipla, are the largest manufacturing companies of cardiovascular drugs in the global market. In the last few decades, the scope of cardiovascular drugs has improved considerably and innovative ways of treatment are being developed continuously. Cardiovascular medicines are prescribed for treating and curing heart failure and hypertension. An array of generic drugs is available in the market such as antiarrhythmic agent e.g. adenosine, losartan, antithrombotic agents, vasoconstrictor tocainide, flecainide, sotalol, amiodarone, diltiazem, or nitroglycerin.

MAJOR PLAYERS IN INDIAN MARKET

1) CIPLAa) Bulk drugs & intermediate. b) Manufacture more than 150 bulk drugs. c) Technology for products & process. 2) CADILA HEALTH CAREa) Bulk drugs & intermediate. b) Contract research. C) Formulations cardiovascular, female health care. d) Contribute to 70% of gross revenue. 3) AVENTIS HEALTH CARE Anti-infective, cardiology, oncology, CNS, respiratory, bone & joints. 4) NICHOLAS PIRAMAL LTD. Cardiology, thrombosis, CNS, Diabetes Segment generates 76% of revenue.

COMPANY PROFILE...

COMPANY PROFILE [2]

About Kamron
Kamron Laboratories Ltd., has been set up in 1990 for manufacture of pharmaceutical formulations in dosage forms like Tablets, Capsules, Liquid Orals, Dry Syrups, Eye Drops and Injections. Kamrons manufacturing facilities are located at Rakanpur which is at a distance of 8 kilometers from city limits of ahmedabad town. Ahmedabad is the largest town of Gujarat state in India and is well connected by direct international flights to Europe, USA, Middle East and Far East. Kamron has tied up with distributors/promoters in several countries for marketing its products in the international market. Kamron has a defined objective of supplying its products throughout the world from its manufacturing location at Rakanpur. The promoter and chairman cum managing director of kamron laboratories ltd. is Mr. kamlesh j. Laskari who is an M.B.A. and has traveled widely across the world. He is having more than 25 years experience in the pharmaceutical field. He is assisted by a team of well qualified, trained and experienced functional heads. The job functions and responsibilities are well defined and there is an organization chart of the management.

Core Values of Kamron Laboratories Ltd

We put our employees first - all the time and act in the interests of enhancing their career progress. We respect the personality, talent, and teamwork of all members, and value a corporate culture that is free, energetic and dynamic. Our customers doctors and retailers are as important to us as our employees and we strive our utmost every day to be a company essential to our customers.

 We shall be known as a company that meets the needs of our customers by listening, communicating, cooperating and collaborating with our partners our customers. We remain focused on the customer, committed to exceeding regulatory and quality requirements through motivated, empowered and dedicated employees.
We observe laws and ethics, and strive to grow in harmony with society and

for the benefit of its development.

Vision statement of Kamron

The vision of Kamron is to rank amongst the first three companies in the states where we operate - within the next ten years. By transmitting this vision at every level of Kamron we shall be recognized by our employees, doctors and retailers as the best pharmaceutical company in India. We shall achieve this by: Making trust, quality, integrity and excellence hallmarks of the way we conduct our business. Attracting, developing, motivating and retaining our talent. Continually growing and improving our business. Demonstrating effectiveness in how we use our resources and make business decisions. By implementing our strategy Operation Trishul to perfection so that we become a Rs. 50 crore company by 2014.

Mission statement Kamron

Our mission is to become a strong regional player in the states where we operate. We will build strong brands and be amongst the top three brands in the segments and in the states where we operate. Our focus will be on prescription generation so that we become a healthy organization. Honesty & integrity will be the most important personality of Kamron.

Facilities
Kamron has got facilities to manufacture Solid Dosage Forms. Liquid Orals and Small Volume Parenterals. Manufacture is carried out as per current good manufacturing practices using state of art automatic machines. Detailed validation is carried out for each machine. The manufacturing process is also validated so as to ensure consistent quality.

Research & Development

Kamron has got a well equipped lab wherein process R & D is carried out. Some of the work being done include. 1. Taste Masking 2. Development of Sustained Release Products 3. Aqueous Coating and Aromatic Coating 4. Product Stability Kamron is the first company in India to launch ciprofloxacin dispersible tablets the technology for which was developed in house by using taste masking. Process R & D is a continuous exercise. Several foul smelling products have been made good smelling by use of aqueous and aromatic coating technology.

Quality Assurance
Kamron Laboratories Ltd. is committed. To provide best quality of medicine & service to our patient for better quality of life so as to ensure customers satisfaction. To improve quality of our products in our pharmaceutical business by use of latest technologies automated process & properly trained & qualified man power. To follow national & international standard for continual improvement in quality management system.

International Certifications
Kamron has got several international certifications which are a testimony to the above policy. Kamron has got: World Health Organization Good manufacturing practice certificate obtained in Decemeber-2004
ISO-9001-2000 Certification from BVQI obtained in October 2005.

Brand Management Team

They have divided our products in three different groups as follows. 1) Panchratna Brands 2) Platinum Blue Group 3) Platinum Green 4) Titanium Brands: Any of the new brand will be considered under Titanium Group Titanium Brands (New Introduction) Facitab IV Inj. Nexa MF Tab Gudgut Cap / Sachet Lolip 10 (Atorvastatin) Kamipril 2.5 & 5 (Ramipril) Thyrofeast (L-Tyrosine with Multivitamines) LXL 500 Vomsafe group Brokam Syp Any of the new brand will be considered under Titanium Group
[Table no-2]

Panchratna Brands Serra Group Lycofeast Group Marin Group Racifree / Rito Group

Platinum Blue Allorgic Group Azikam group Feast Ambrokam T Arthigo G Sylron TX

Platinum Green Zidon Group Apin PM Feprovit Syrup QXL group Onkam group TNN group

Product list
PROTEOLYTIC ANTI EMETIC

Serra-5/10/20 Serratiopeptidase Serra-D Serratiopeptidase Diclofenac Potassium Serra-N Serratiopeptidase Nimesulide Serra-DP Serratiopeptidase Diclofenac Sodium Paracetamol Serra-A Serratiopeptidase Aceclofenac

Tab. Zidon-DT 5/10/20 mg. Domperidone Disp. Tab. Scored

Tab. 10 mg. Tab. 4/8 mg. Inj. 2 mg./2 ml.//4 mg./4

10 mg. Onkam-4/8 50 mg. Ondansetron Onkam-2/4 Tab. Ondansetron 15 mg. ml. 100 mg. Onkam

30 ml. Syp. 2 mg. / 5 ml. Tab. 10 mg. 10 mg. Tab. 10 mg. 10 mg. 2.5 mg. Tab. 20 mg. 20 mg.

Tab. Ondansetron 10 mg. Vomsafe

50 mg. Doxylamine Succinate 500 mg. Pyridoxine HCL Tab. Vomsafe Plus 15 mg. Doxylamine Succinate 100 mg. Pyridoxine HCL Folic Acid Vomsafe OD Doxylamine Succinate Pyridoxine HCL

GASTRO INTENSTINAL

ANTIBIOTICS

Kamtac-150 Ranitidine Omebloc Omeprazole Zidon-O

Tab. Amiron-100/250/500

Inj.

150 mg. Amikacin 100 mg./250 mg./500 mg./2 ml. Cap. inj. Tab. 250/500 mg.

20 mg. Azikam Cap. Azithromycin

Domperidone Omeprazole Zidon-RD Domperidone Omeprazole Zidon-P Pantoprazole Domperidone Zidon-PZ Pantoprazole Domperidone Zidon Plus Domperidone Paracetamol

10 mg. Linkam

Inj.

10 mg. Lincomycin 300 mg./ml Inj. 1 ml./2 ml. Cap. Linkam-500 10 mg. Lincomycin 20 mg. Live-OD Cap. 500 mg. Tab. 200 mg. Tab. 200 mg. Tab. 200 mg. 600 mg. Tab. 250 mg./500 mg. Tab. 500 mg. 600 mg. Tab. 50 mg. Kid Tab. 150 mg. Inj. 1 gm. 1 gm./2 ml. Vial Cap. 250 mg. 250 mg. 60 Million Spores

Tab. Levofloxacin 20 mg. QXL-200 10 mg. Ofloxacin Tab. QXL-TZ 40 mg. Ofloxacin 10 mg. Tinidazole Tab Q-Bid-250/500 10 mg. 500 mg. Ciprofloxacin Q-Bid-TZ Ciprofloxacin Tinidazole

ANTI-COUGH ANTISTAMINIC ANTI-COLD

100 ml. Syp. Roxilide-Kid Roxithromycin Tebrutaline Sulphate 2.5 mg. + Brokam Bromhexine HCL 8 mg. + Guaiphenesin 100 mg. + Menthol 5 mg./10 ml. Ambrokam Dispersible Roxilide-150 Roxithromycin

100 ml. Syp. Sulcef Ambroxol HCI 30 mg. + Salbutamol 2 Cefoperazone mg. + Guaiphenesin 50 mg. /5 ml. Ambrokam-P Sulbactum

60 ml. Xyclox-LB Ambroxol HCI 15 mg. + Salbutamol Amoxycillin 1mg. + Guaiphenesin 50 mg. + Menthol Cloxacillin 1 mg./5 ml. Lactic Acid Bacillus Ekocet-DT Tab.

Cetirizine Dihydrochloride Disp. Kamolate Phenylephrine HCL 5 mg. + CP Maleate 2 mg. + Caffeine 15 mg. + Paracetamol 500 mg. Colstat Paracetamol 125 mg. + Pseudoephedrine 15 mg. + Chlorpheniramine Maleate 2 mg./5 ml. Voltriz-5 Levocetirizine Tab. 5 mg. 60 ml. Syp. Tab. 10 mg.

DIGESTIVE ENZYME

Kamozyme Fungal Diastase (1:1200) Pepsine (1:3000) Kamozyme Fungal Diastase (1:1200) Pepsine (1:3000) Kamozyme-EP Pancreatin Bile Constituents Activated Dimethicone

15 ml. Drops 33.3 mg. 5 mg./1 ml. 200 ml. Syp. 50 mg. 10 mg./5 ml. Tab. 192 mg. 25 mg. 40 mg.

ANTI - MALARIAL

NUTRITIONALS

Kay-Mal - Arteether

Inj. 150 mg./2 ml. Tab. 100 mg.

Feast

Tab. Mefkam -Q Mefloquine

Vit. A (As acetate) 5000 i.u. + Vit. E (As acetate) 25 i.u. + Vit. C 100 mg. + Vit. B1 10 mg. + Vit B2 10 mg. + Vit. B6 3 mg. + Vit B12 5 mcg. + Folic Acid 1 mg. + Niacinamide 50 mg. + Calcium Pantothenate 12.5 mg. + Zinc Oxide 15 mg. + Cupric Oxide 2.5 mg. + Sodium Selenate 60 mcg. + Mag. Chloride 1.4 mg. + Chromium Chloride 65 mcg. Feprovit 200 ml. Syp.

ANTI-GOUT

Allgoric Allopurinol

Tab. 100 mg.

ANALGESIC ANTI INFLAMMATORY

Protein Hydrolysate 0.5 gm. +

Tramace

1/2 ml. Inj.

Riboflavin 2.5 mg. + Phridoxine HCL 1 Tramadol HCL 50 mg./1 ml. 100 mg./2 ml mg. + Cyanocobalamine 2.5 mcg. + Folic Acid 0.5 mg. + Niacinamide 25 mg. + D-Panthenol 2.5 mg. + Ferros Tramace-50 DT Tramadol HCL Tab. 50 mg.

Gluconate 100 mg. + Calcium Gluconate 100 mg./15 ml Marin Cap.

Dicron-C Diclofenac Potassium Paracetamol Chlorzoxazone

Tab. 50 mg. 325 mg. 250 mg. 3 ml. Inj. 25 mg./ml. Tab. 100 mg. Tab. 100 mg

Silymarin 70 mg. + Vit. B1 5 mg.+ Vit

B2 5 mg. + Vit B6 1.5 mg. + Vit. B12 5 Dicron mcg. + Niacinamide 25 mg. + Cal. Pantothenate 7.5 mb. Marin Diclofenac Sodium Docron- SR 100 ml. Susp. Diclofenac Sodium Nikam Nmesulide

Silymarin 35 mg. + Thiamine HCI 1.5 mg. + Riboflavin 1.5 mg. + Phridoxine HCI 1.5 mg. + Niacinamide 20 mg. + D-Panthenol 5 mg. + Vitamin B12 1 mcg Marin Forte Silymarin 140 mg. + Thiamine

ANTI - PYRETIC

Tab. TNN Nimesulide

Tab. 100 mg. 500 mg. 60 ml. Susp. 10 mg. 125 mg. / 5 ml

Mononitrate 5 mg. + Riboflavin 5 mg. + paracetamol Pyridoxine HCI 1.5 mg. + Niacinamide 25 mg. + Calcium Pantothenate 7.5 mg. + Vitamin B12 5 mcg. Mekam Tab. TNN Nimesulide paracetamol

Mecobalamin 500 mcg. + Thiamine Mononitrate 10 mg. + Pyridoxine HCI 3 mg. + Niacinamide 45 mg.+ Calcium Panthothenate 50 mg. Mekam Inj.

CALCIUM SUPPLEMENTS

Tufcal-Forte MCHC eq. to Calcium 198 mg. +

Tab.

Phosphorus 90 mg. + Zinc Sulphate 20 mg. 200 ml. Susp.

Mecobalamin 1000 mcg. + Thiamine

HCI 100 mg. + Pyridoxine HCI 100 mg. Tufcal + Niacinamide 100 mg. + D-Panthenol 50 mg./2 ml. Mekam-DM Tab.

MCHC eq. to Calcium 99 mg. + Phosphorous 45 mg. + Zinc Sulphat 20 mg. + Lysine Mono HCL 150 mg./10 ml. Tufcal -M Tab.

Mecobalamin 500 mcg. + Alpha Lipoic

Acid 100 mg. + Folic Acid 1.5 mg. + Vit. B6 6 mg. + Vit. B1 10 mg. + Vit. E 25 i.u. MV-12 Part-I : Vitamin C 150 mg. Part-II : Vitamin B12 2500 mcg. + Folic Acid 0.7 mg. + Niacinamide 12 mg. Inj.

Ele. Calcium 500 mg. + vit. D3 250 I.U. + Magnesium (Elemental) 40 mg. + Manganese (Elemental) 1.8 mg. + Zince Sulphate 7.5 mg. + Copper Sulphate 1 mg. Boron 250 mcg.

HAEMOSTATIC

ANTI - SPASMODIC

Sylron-250/500 Etamsylate

Tab. 250/500 mg. 2 ml. Inj. 125 mg./1 ml. Tab.

Kamspas -250/500 Mefenamic Acid Dicyclomine Kamspas-T Mefenamic Tranexamic Acid Draw Drotaverine

Tab. Sylron 250/500 mg. Etamsylate 10 mg/20 mg. Sylron-T

Tab. Tranexamic Acid 250 mg + Etamsylate 250 mg. 250 mg 500 mg. Inj. 40 mg./2 ml Kool Calcium Dobesilate OTHERS Cap. 500 mg.

HAEMATINIC

Facicap-CI

Cap.

Alzomax- 25/50 Alprazolam Fluron-10 Flunarizine with Beta Cyclodextrine

Tab. 0.25/0.50 mg. Tab. 10 mg. Inj. 50 mg./1 ml. 200 mg./4 ml. Cap.

Carbonil Iron (Eq. to ele. Iron) 100 mg. + Folic Acid 1.5 mg. + Vit. B12 15 mcg. + Vit. C 75 mg. + Zinc Sulphate 61.8 mg. Facicap Each 15 ml. Contains:

200 ml. Liq. Utegest Natural Micronized Progesterone Utegest 20/100/200 mg.

Ferrous Gulconate 300mg. + Vit. B12 15 mcg. + Niacinamide 45 mg. + Riboflavin 5 mg.+ Vit. B1 5 mg. + Vit. B6 1.5 mg. Facicap-Z

Natural Micronized Progesterone 20/100/200 mg.

Cap. Deca-Kamolin

Inj.

Ferrous Fumarate 152 mg. + Zinc Sulphate 15 mg. + Vit. B12 mcg. + Folic Acid 1.5 mg.

Nandrone Deconate Riten Ritodrine Hydrochloride Riten Ritodrine Hydrochloride

50 mg./ml. Tab. 10 mg. Inj. 10 mg./ml.

DATA ANALYSIS

(A) OBJECTIVES

As a student my objective was to acquire practical knowledge of marketing field and to know the relation between theoretical and practical concepts. Moreover to be familiar with corporate world. From the companys point of view my objectives were: 1. Perform a market research to determine market share of given Molecule- Ramipril and Ramipril Hydrochlorothiazide

2. To seek the major prescribers of these molecules for the given molecule.

3. To know the market value of the given molecule before the launching of this new molecule. 4. To know what are the regular sale and new prescription wise sale.

(B) RESEARCH METHODOLOGY:

The research began with the distribution of the allotted area into small parts. Then the survey of 150 chemists was conducted. In that survey it was tried to seek out maximum information from chemists related to molecule and to get information related to status the different brands. At the same time, prescribers of these molecules were known from the chemists and their medical specialties were known, so that the detailed and in depth analysis could be carried out. During the study it was also taken care to find out market share of different brands, their pricing strategy and tried to understand their marketing strategies, so as to implement them to increase our market share.

WORKING AREA:
I had been given the following area for the survey of all the chemists underlying in these areas. 1. Specific areai. Chandkheda ii. Sabarmati iii. Vadaj iv. Ranip 2. Common areai. VS Hospital ii. Doctor house iii. Stadium area

RESEARCH DESIGN:
The tool used for conducting survey is questionnaire which shown in appendix. The questionnaire is simple and contains open ended question. It is designed such that it can be easily understood by the respondent.

(C) PLAN OF WORK:

1-6-2010- Reporting day in the company On that day I got some idea about how to conduct the survey and what to do during survey, how to report. 2-6-2010 to 3-6-2010-Pilot survey My work was started with pilot survey conducted in Ahmedabad region. In pilot survey my objective was to know brand names of different companies and their prices. 4-6-2010- Reporting to the company about work. On that day I have learnt about questionnaire designing. 7-6-2010 to 22-6-2010- Survey In these days I have surveyed different area allotted to me by the company. Actual data collection is done during these days. I have covered all the area allotted to me. During these days I have also reported to the company about my completed work on alternate day. 23-6-2010 to14-7-2010- Preparation of report During these days I have done my data analysis and prepare my report. I have search for the molecule information, latest market etc. 15-7-2010- Submission of report in the college

(D)ABOUT THE MOLECULES

Ramipril [3] [4] [5]
Ramipril is in a group of drugs called ACE inhibitors. ACE stands for angiotensin converting enzyme. Ramipril is used to treat high blood pressure (hypertension), heart failure, and to improve survival after a heart attack.

[3]

Ramipril is a potent and long-acting inhibitor of the angiotensin convertingenzyme (ACE). It is a prodrug, which is hydrolyzed in the liver after absorption from the gastro-intestinal tract to form the active angiotensin converting enzyme inhibitor, ramiprilat. Hydrochlorothiazide (HCTZ) is a thiazide diuretic and an antihypertensive. The components have quite different but complementary antihypertensive mechanisms, and the improved efficacy is not due simply to additive antihypertensive effects. Ramipril blocks the counterregulatory rise in angiotensin II triggered by diuretic therapy. Diuretics appear to enhance the antihypertensive action of ACE inhibitors particularly when the renin-angiotensin system is inactive. As a result, patients who do not respond to monotherapy often do respond to combination therapy. A further benefit is that the dosages of components in a combination can be lowered for some patients, thus reducing the risk of adverse effects. Ramipril as well as its metabolite ramiprilat has been shown to be pharmacokinetically compatible with hydrochlorothiazide, they both require once daily dosage and achieve maximum hypotensive effect approximately 4 hours after administration.

CLINICAL PHARMACOLOGY
Ramipril Following oral administration of Ramipril, peak plasma concentrations of Ramipril are reached within one hour. The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract, although the rate of absorption is reduced. Cleavage of the ester group (primarily in the liver) converts Ramipril to its active diacid metabolite, ramiprilat. Peak plasma concentrations of ramiprilat are reached 2-4 hours after drug intake. The serum protein binding of Ramipril is about 73% and that of ramiprilat about 56%. Ramipril is almost completely metabolized to ramiprilat, which has about 6 times the ACE inhibitory activity of Ramipril. After oral administration of Ramipril, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the faeces. Less than 2% of the administered dose is recovered in urine as unchanged Ramipril. Blood concentrations of Ramipril and ramiprilat increase with increased dose, but are not strictly dose-proportional. The 24-hour AUC for ramiprilat, however, is dose-proportional over the 2.5-20 mg dose range. The absolute bioavailabilities of Ramipril and ramiprilat were 28% and 44%, respectively, when 5 mg of oral Ramipril was compared with the same dose of Ramipril given intravenously. The initial rapid decline of Ramipril due to tissue distribution has a half-life of 2-4 hours. The apparent elimination phase has a half-life of 9-18 hours. The terminal elimination phase has a prolonged half-life (>50 hours). It does not contribute to the accumulation of the drug. After multiple daily doses of Ramipril 510 mg, the half-life of ramiprilat concentrations within the therapeutic range was 1317 hours. After once-daily dosing, steady-state plasma concentrations of ramiprilat are reached by the fourth dose. Steady-state concentrations of ramiprilat are somewhat higher than those seen after the first dose of Ramipril, especially at low doses (2.5 mg), but the difference is clinically insignificant. In patients with creatinine clearance less than 40 ml/min/1.73m2, peak levels of ramiprilat are approximately doubled, and trough levels may be as much as quintupled. In multiple-dose regimens, the total exposure to ramiprilat (AUC) in these patients is 3-4 times as large as it is in patients with normal renal function who receive similar doses. The urinary excretion of Ramipril, ramiprilat, and their metabolites is reduced in patients with impaired renal

function. Compared to normal subjects, patients with creatinine clearance less than 40 ml/min/1.73m2 had higher peak and trough ramiprilat levels and slightly longer times to peak concentrations. In patients with impaired liver function, the metabolism of Ramipril to ramiprilat appears to be slowed, and plasma Ramipril levels in these patients are increased about 3-fold. Peak concentrations of ramiprilat in these patients, however, are not different from those seen in subjects with normal hepatic function, and the effect of a given dose of plasma ACE activity does not vary with hepatic function. Hydrochlorothiazide Thiazides affect the renal tubular mechanism of electrolyte reabsorption. Thiazides increase excretion of sodium and chloride in approximately equivalent amounts. Natriuresis causes a secondary loss of potassium. The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not affect normal blood pressure. The onset of action of thiazides occurs in 2 hours and the peak effect at about 4 hours. The action persists for approximately 6-12 hours. Hydrochlorothiazide is rapidly absorbed, as indicated by peak plasma concentrations 1-2.5 hours after oral administration. Plasma levels of the drug are proportional to dose; the concentration in whole blood is 1.6-1.8 times higher than in plasma. Thiazides are eliminated rapidly by the kidney. After oral administration of 12.5 to 100mg doses, 72-97% of the dose is excreted in the urine, indicating dose independent absorption. Hydrochlorothiazide is eliminated from plasma in a biphasic fashion with a terminal half-life of 10-17 hours. Plasma protein binding is 67.9%. Plasma clearance is 15.930.0 L/hr; volume of distribution is 3.6-7.8 L/kg. Gastrointestinal absorption of hydrochlorothiazide is enhanced when administered with food. Absorption is decreased in patients with congestive heart failure, and the pharmacokinetics are considerably different in these patients.

INDICATION
Indicated for the treatment of mild to moderate hypertension in patients (in whom combination therapy is appropriate) who have been stabilised on the individual components given in the same proportion.

CONTRAINDICATIONS
Ramipril or Ramipril + Hydrochlorothiazide must not be used in patients with hypersensitivity to Ramipril, hydrochlorothiazide or other thiazide diuretics, sulphonamides or any of the excepients and allergy to starch. History of hereditary angioneurotic oedema.Severe impairment of renal function with a creatinine clearance below 30ml/min/1.73m2 body surface area and in dialysis patients

(hydrochlorothiazide ineffective). Haemodynamically relevant unilateral or bilateral renal artery stenosis, mitral stenosis, aortic stenosis, and in patients with low blood pressure (hypotensive patients) or in patients with an unstable circulatory situation (haemodynamically unstable patients) where there might be a risk of life threatening fall in blood pressure and renal failure. Clinically relevant electrolyte disturbances e.g. hypokalemia, hyponatremia or hypercalcemia which may worsen following treatment. Severe impairment of liver function (risk of fluid and salt imbalance).Rapid onset allergy (anaphylactoid) like hypersensitivity reactions sometimes progressing to shock have been described in the course of dialysis with certain high flux membrane (polycrilonitril membranes) during therapy with ACE inhibitors such as Ramipril.

Pregnancy & Lactation

Ramipril or Ramipril + Hydrochlorothiazide should not be used in pregnancy as it affects development of the foetus. If the patient becomes pregnant during treatment, Ramipril or Ramipril + Hydrochlorothiazide mg must be replaced at the earliest with some other group of antihypertensive agents. If treatment with Ramipril or Ramipril + Hydrochlorothiazide is necessary during the lactation period, the infant should not be breastfed.

PRECAUTIONS
Treatment with Ramipril or Ramipril + Hydrochlorothiazide requires regular medical supervision. Generally dehydration, reduced blood volume (hypovolumia) or salt depletion should be corrected before initiating the treatment (in patients with concomitant heart failure, however, this must be carefully weighed against the risk of volume overload). Special caution is necessary during the treatment of:

Patients with severe and particularly with malignant hypertension. Patients with concomitant and particularly with severe heart failure. Patients in whom fluid or salt deficiency exists or may develop (as a result of inadequate fluid or salt intake) or as a result of diarrhoea, vomiting or excessive sweating in cases where salt and fluid replacement is inadequate. Patients with haemodynamically relevant renal artery stenosis. Close medical supervision is also necessary in patients with

haemodynamically relevant stenosis of coronary arteries or of the blood vessels supplying the brain.In patients with pre-existing impairment of renal function or in kidney transplant patients. Serum sodium, potassium, calcium, uric acid, and blood sugar should be monitored regularly. More frequent monitoring of potassium is necessary in patients with impaired renal function. White blood cell count should be monitored (more frequent in the initial phase of the treatment) so that leucopenia can be detected.

ADVERSE REACTIONS
The following adverse effects can be observed during therapy with Cardiovascular Symptomatic hypotension characterised by light-headedness sometimes accompanied by concentration disturbances as well as impaired reactions, fatigue, dizziness, weakness may occur as a result of vasodilatation after the initial dose of Ramipril or Ramipril or Ramipril + Hydrochlorothiazide. Other symptoms may include tachycardia, palpitation, orthostatic hypotension, nausea, headache, tiredness or tinnitus after excessive reduction of blood pressure. This occurrence may be more likely in patients with: Severe and malignant hypertension Concomitant and particularly severe heart failure Previous diuretic therapy Fluid or salt deficiency Haemodynamically relevant renal artery stenosis. Pre-existing coronary artery disease or cerebrovascular disease, a sudden fall in blood pressure may cause perfusion disturbances to the heart (angina

pectoris or myocardial infarction) or the brain (transient ischemic attacks or stroke). Renal During treatment with Ramipril or Ramipril + Hydrochlorothiazide there may be deterioration in renal function under certain circumstances progressing to lifethreatening acute renal failure. This applies particularly in patients with renovascular diseases (haemodynamically relevant renal artery stenosis, in renal transplant patients and in patients of cardiac failure). In isolated cases, interstitial nephritis may develop during therapy with hydrochlorothiazide. Preexisting pronounced urinary protein excretion might increase under treatment with Ramipril or Ramipril +

Hydrochlorothiazide however renal protein excretion may also be reduced in patients of diabetic nephropathy. Ramipril or Ramipril + Hydrochlorothiazide may lead to a decline in serum sodium concentration particularly in conjunction with restricted salt intake. Hydrochlorothiazide may contribute to the development of hypochloremia, hypomagnesemia as well as hypercalcemia. In addition Ramipril or Ramipril + Hydrochlorothiazide may contribute to development or aggravation of a metabolic alkalosis. Ramipril may contribute to an increase in concentration of serum potassium while hydrochlorothiazide may contribute to a decrease in serum potassium. Thus during the therapy with Ramipril or Ramipril + Hydrochlorothiazide both a decline and increase in serum potassium are possible, the latter effect being mainly encountered in patients with impaired renal function (e.g. diabetic nephropathy) or those receiving potassium sparing diuretics or potassium salts concomitantly. Warning signs of electrolyte disturbances (e.g. changes in serum levels of sodium, potassium, calcium and magnesium) include thirst, headache, confusion, muscle cramps, tetany, muscle weakness and gastrointestinal symptoms. Gastrointestinal Reactions in digestive tract may develop e.g. dryness of mouth, irritation or inflammation of oral mucosa, constipation, diaorrhea, nausea and vomiting, gastritis like abdominal pain, pancreatitis, increase in hepatic enzymes and/or bilirubin, cholestatic jaundice and other forms of impaired liver function and in some instances life threatening hepatitis.

Blood picture The following changes in blood picture may occur: a mild to severe reduction in red blood cell count and haemoglobin content, blood platelets and white blood cell count, impaired blood cell formation (bone marrow depression) and excessive reduction in number of all blood cells (pancytopenia) have been observed. Such changes in blood picture that are sometimes life-threatening are more likely to occur in patients of impaired renal function, in patients with concomitant connective tissue disorder or in patients treated with other drugs that may cause changes in blood picture. Others Disturbance of balance, visual disorders, headache, nervousness, restlessness, tremor, sleep disturbances, confusion, and loss of appetite, depressed mood, feeling of anxiety, abnormal sensations, taste change and muscle cramps. Erectile impotence and reduced sexual desire (decreased libido) may occur. Inflammation of blood vessels (vasculitis), muscle and joint pains (myalgia and arthralgia), fever, eosinophilia may occur. During treatment with hydrochlorothiazide and thus, with Ramipril or Ramipril + Hydrochlorothiazide increased blood concentrations of uric acid levels may occur. This may lead to gout attacks particularly in those patients whose uric acid levels are already elevated. Hydrochlorothiazide might lower the tolerance of glucose. In patients with diabetes mellitus this may lead to deterioration of metabolic control. A latent diabetes mellitus may become manifest for the first time. Hydrochlorothiazide may cause an increase in serum cholesterol and triglycerides. Raised titres of antinuclear antibodies have been seen with other ACE inhibitors. In temporal relationship with the use of hydrochlorothiazide, the development of lupus erythematosus has been described. Effects on the ability to drive and operate machinery: The antihypertensive effect in individual cases may be symptomatic. Treatment with Ramipril or Ramipril + Hydrochlorothiazide may therefore, affect the ability to drive, cross the road safely or operate machinery, especially at the start of treatment or when changing over from other preparations, or during concomitant use of alcohol.

INTERACTIONS Combination with diuretics or other antihypertensive agents or nitrates and tricyclic antidepressants may potentiate the antihypertensive response to Ramipril or Ramipril + Hydrochlorothiazide. Patients previously treated with diuretics may experience a marked drop in blood pressure. Potassium-sparing diuretics such as spironolactone, amiloride and triamterene or potassium supplements may increase the risk of hyperkalemia. Ramipril or Ramipril + Hydrochlorothiazide may weaken the effectiveness of blood sugar lowering medications (antidiabetic agents, e.g. insulin and sulphonylurea derivatives). A high intake of dietary salt may decrease the effects of antihypertensive medication. Leukopenia may be aggravated in patients undergoing treatment with

immunosuppressants, cytostatic agents, systemic corticosteroids or allopurinol. Concurrant administration of methyldopa may result in hemolysis. Since ACE inhibitors decrease the excretion of lithium salts, lithium concentrations in the blood should be monitored in patients undergoing such therapy. When Ramipril or Ramipril + Hydrochlorothiazide are administered simultaneously with nonsteroidal

antihypertensive drugs (e.g. acetyl salicylic acid or indomethacin) attenuation of antihypertensive effect and moreover acute renal failure may occur. Ramipril or Ramipril + Hydrochlorothiazide may potentiate the effects of alcohol. DOSAGE AND ADMINISTRATION Hypertension: The recommended initial dosage is 1 capsule/tablet of Ramipril or Ramipril + Hydrochlorothiazide once a day. It is started with Ramipril alone first then if required then with diuretics. The dose can be up titrated at intervals of 2-3 weeks to Ramipril 5mg and hydrochlorothiazide 12.5mg and then to a maximum of Ramipril 10 mg and hydrochlorothiazide 12.5 mg. If required another antihypertensive agent may be added. In patients pre-treated with a diuretic, consideration must be given to discontinuing the diuretic at least 2-3 days (depending on the duration of action of the diuretic) longer before initiating the treatment with Ramipril or Ramipril + Hydrochlorothiazide. If discontinuation is not possible the treatment should be

initiated with the smallest possible dose of Ramipril (1.25mg daily) in a free combination. Subsequently a changeover to an initial daily dose of Ramipril or Ramipril + Hydrochlorothiazide not exceeding one capsule should be made. Dosage in patients with impaired renal function: For patients with creatinine clearance between 60 and 30ml/min/1.73m2 body surface area, treatment is initiated with Ramipril alone 1.25mg. After gradually increasing the dose of Ramipril, medication with Ramipril or Ramipril + Hydrochlorothiazide is initiated at a daily dose of 1 capsule. The maximum permitted daily dose is 2 capsules of Ramipril or Ramipril + Hydrochlorothiazide in such patients. Administration Generally, the prescribed daily dose should be taken in the morning as a single dose. The capsules must be swallowed as a whole with sufficient amounts of liquid (approx glass). They may be taken before during or after a meal.

DATA INTERPRETATION

(E) AVAILABLE BRANDS IN THE MARKET

BRAND NAME
CARDACE HOPACE RAMIPRES RAMACE RAMISTAR RL RAMCOR RACE ODIPRIL MACPRIL ZIRAM ZOREM RAMIHEART

COMPANY NAME
Sanofi Aventis Micro Cardicare Cipla Astra Zeneca Lupin Sunij Pharma Epca Alkem Blue Cross Macleods Fdc Intas Mankind

AVAILABLE STRENGTH
2.5mg, 5mg, 2.5H, 5H 2.5mg, 5mg, 2.5H, 5H 2.5mg, 5mg, 2.5H 2.5mg, 5mg, 2.5H 2.5mg, 5mg, 2.5H, 5H 2.5mg, 5mg, 2.5H 2.5mg, 5mg, 2.5H, 5H 2.5mg, 5mg, 2.5H 2.5mg, 5mg, 2.5H, 5H 2.5mg, 5mg, 2.5H, 5H 2.5mg, 5mg 2.5mg, 5mg 2.5mg, 5mg
[Table no-3]

Notes: Here,
2.5 mg= 2.5 mg of Ramipril 5 mg= 5 mg of Ramipril 2.5 H= 2.5 mg of Ramipril + 12.5 mg of Hydrochlorothiazide 5 H= 5 mg of Ramipril + 12.5 mg of Hydrochlorothiazide

(F) DATA ANALYSIS

1) Sale of number of strips per week of different companies

From sale of no. of strips per week we can know what is the total market share captured by the brands.

Brand Name

Company Name

Sale of strips per week

Cardace Hopace Ramipres Ramace Ramistar Rl Ramcor Race Odipril Macpril Ziram Zorem Ramiheart

Sanofi Aventis Micro Cardicare Cipla Astra Zeneca Lupin Sunij Pharma Epca Alkem Blue Cross Macleods Fdc Intas Mankind Total

391 114 275 135 281 215 62 70 22 250 131 32 9 1987

[Table no-4]

Sale of number of strips per week of different companies

450

400

391

350

300 275

281 250 215

Sale of strip per week

250

200 sale/ week 150 114 100 135

131

62
50

70 32 9

22 0

Brand Name

[Graph 1]

Percentage of total sale

Brand Name Sale of strips per week Cardace Hopace Ramipres Ramace Ramistar Rl Ramcor Race Odipril Macpril Ziram Zorem Ramiheart Total 391 114 275 135 281 215 62 70 22 250 131 32 9 1987 Percentage of total sale/week 19.67791 5.737292 13.83996 6.794162 14.14192 10.82033 3.120282 3.522899 1.107197 12.58178 6.592854 1.610468 0.452944 100 %
[Table no-5]

Percentage of total sale

1.61 0.45
6.59 19.67 12.58

Cardace
Hopace Ramipres Ramace 5.73 Ramistar Rl Ramcor Race Odipril

1.1
3.52 3.12 10.82 14.14 6.79

13.83

Macpril Ziram

[Graph 2]

2) Sale Of Strip Of Ramipril And Ramipril Hydrochlorothiazide

This analysis indicates strength wise sale of given brands. That interprets which strength of the brand sell out more. This helps in estimating which strength prescribed more by the doctor or running more in the market.
Strength 2.5 mg Ramipril 5 mg Ramipril 2.5 mg of Ramipril + 12.5 mg hydrochlorotiazide 5 mg of Ramipril + 12.5 mg hydrochlorotiazide Total 1987 100
[Table no-6]

Sales 1399 426 156

Percentage of sale 70.40 21.43 7.85

0.30

Percentage of sale(Strength Wise)

0% 8%

22%

2.5 5 2.5H 5H 70%

[Graph 3]

3) Sale Of Strip Of Ramipril And Ramipril Hydrochlorothiazide (Dosage form wise)

By this analysis we can know that which dosage form is prefer more in the market. It helps in determining which dosage we can launch in the market that will succeed.

Form TAB CAP

2.5 792 187

5 237 55

2.5H 102 8

5H 10 0

Total 1141 250

% 88.85 11.15 100

[Table no-7]

Sales(Dosage Form Wise)

11.15

Tablet Capsule

88.85

[Graph 4]

4) Unit Percentage Value

Unit percentage value is the value which gives information about percentage of total revenue generated from sale of the brand. It is calculated from total unit sale of the product and price per unit.

Brand Name
2.5 Cardace Hopace Ramipres Ramace Ramistar Rl Ramcor 6.54 4.5 4.52 6.73 5.5 2.4 2.5

Price

Unit Sale

Value

Unit % Sale

5 10.78 8 7.51 11.13 8.2 4.4 5

2.5H 6.6 4.8 4.99 4.5 6.1 2.9

5H 11.4

2.5 2750 770 1900 1455 1860 1470 470

5 820 290 650 420 560 480 110

2.5H 290 80 200 100 380 200

5H 50 29308.6 6169 14467.5 14916.75 17140 6220 1901 28.57 6.01 14.10 14.54 16.71 6.06 1.85

4.4 Race Odipril Macpril Ziram Zoram Total 5.4 2 1.1 1.78 5.21 6.5 3 2.2 3.49 8.66 5.5 2.5 1.75 530 150 1770 1020 270 140 50 530 290 50

40 50 20 200 4047 500 3486 2836.7 1581.2 102573.75 3.95 0.49 3.40 2.77 1.54 100

[Table no-8]

Unit % Value
30

25

20

Unit % Value

15

10

Brand Name

[Graph 5]

5) Analysis of regular sale and new prescription.

In this analysis we can know regular customer and new customer of this molecule Table noBrand Name Total sale Total sale(new prescription) Cardace Hopace Ramipres Ramace Ramistar Rl Ramcor Race Odipril Macpril Ziram Zorem Ramiheart Total 391 114 275 135 281 215 62 70 22 250 131 32 9 1987 256 79 194 95 183 168 42 43 16 178 95 21 9 1391 Total sale (regular) 135 35 81 40 98 47 20 27 6 72 36 11 0 596
[Table no-9]

Total sale(Regular Vs New Prescription)

300

250

200

sale

150

100

50

Brand Name Total sale(new prescription) Total sale (regular)

[Graph 6]

FINDINGS

As per the survey conducted, the market share of different companies is quite different. Many companies are available in the market but few brands are running good. The market share of SANOFI AVENTIS under the brand name of CARDACE is around 20 %. Then other brands are also having good position like RAMISTAR (LUPIN) 14.14% RAMIPRES (CIPLA)- 13.83% MACPRIL (MACLOEDS)- 12.58% Most Prescribed strength in Ramipril is 2.5mg because the treatment is started with normal dose. Then the doctor moves to higher dose. Based on severity Ramipril hydrochlorothiazide is prescribed. I also came to know that doctors are also prescribing hypertensive drugs other than the Ramipril also. Price difference is more among the brands. MACPRIL 2.5 mg is available only at Rs.11 while CARDACE 2.5 mg is available at Rs. 65. 88.85 % brands are available in Tablet form while only 11.15 % brands are available in capsule form. All brands are available in 10 TAB/strip except RAMACE which is available in 15 TAB/strip.
Pharmaceutical market is most dynamic and continuously changing market so

nothing is permanent.

SUGGESTIONS
I would like to give following suggestions based on my market survey, 1. Market share of CARDACE is highest though its price is high than others because most doctors prefer more that. So company should think about this price factor and also how to conduct doctors that they prescribe more.

2. Company should think about field force penetration in different areas in which will help in capture the market.

3. For the help of field force I have specified name of major prescribers of each brand so company should give more attention on them.

4. Price range is around 10-30 Rs. for lower brands and for higher brand 40-60

Rs. so keep it around 15-20 Rs.

5. Most preferred strength is 2.5 mg and 5 mg of Ramipril. Ramipril

hydrochlorothiazide is less preferred. So my suggestion is to concentrate on only Ramipril. 6. During my survey I came to know doctors are preferred Tablet form more than capsule so my suggestion is to keep the dosage form to Tablet form. 7. Promotional efforts are zero from the company. So we can include promotional efforts like leaflets, posters, banners etc.

LIMITATION OF SURVEY
This survey is conducted in limited area in Ahmedabad. So it is not total picture or reflection of the market of whole Ahmedabad. So it cannot be generalized. The findings in this study are purely dependent on the answers of the respondents. The information recorded is based on the opinion and reactions of the respondents as on the date of research.

References
1. http://www.themedica.com/drug/cardiovascular-drug/ 2. http://www.kamronlabs.in 3. http://www.drugs.com/ramipril.html 4. http://www.drugs.com/dosage/ramipril.html#ixzz0sRXmqiIk 5. http://www.drugs.com/ppa/ramipril.html#ixzz0sRWRpeFoF

APPENDIX Questionnaire
Name of the Chemist: Date: Area: 1) Which brands of Ramipril and Ramipril + Hydrochlorothiazide you are having: Brand name Company name Dosage forms Tablet Capsule

2) In which strength tablet and capsule are available? Tablet mg of Ramipril + mg of hydrochlorothiazid e Capsule mg of Ramipril + mg of hydrochlorothiazi de

Brand name

Company name

3) Which type of packaging available for tablet & capsule? Brand name Company name Tablet/strip or Capsule/strip

4) What is the MRP of the brands? Brand name

Company name

Rs./Tablet or Rs./Capsule

5) How much quantity of Ramipril you sell per day? 6) Approximately how much quantity of each brand you sell per day? Brand name Company name Tablet/day or Capsule/day

7) How many no of prescription are you handling during the day from Dr.? Prescription No of Brand name Doctors name strength Speciality prescriptions/ day

8) Promotional efforts made by the company:

Thank you very much.